Thymopentin is a synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle.
CAT No: T07011
CAS No: 177966-81-3
Synonyms/Alias: THYMOPENTIN;69558-55-0;TP-5;Timunox;Arg-Lys-Asp-Val-Tyr;Sintomodulina;Thymopentine;Timopentina;Thymopoietin 32-36;IMMUNOX;Hg-thymopentin;Pentapeptide-1;Thymopoietin pentapeptide;Oristar thymopentin;Sh-pentapeptide-1;ORF-15244;DTXSID9046609;NSC-760116;Thymopentinum;(6S,9S,12S,15S,18S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-18-(4-hydroxybenzyl)-1-imino-15-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecan-19-oic acid;DTXCID7026609;Thymopoetin 32-36-pentapeptide;ORF 15244;L-Tyrosine, L-arginyl-L-lysyl-L-a-aspartyl-L-valyl-;Thymopentine [French];Thymopentinum [Latin];Timopentina [Spanish];(3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid;Thymopentin [USAN:INN:BAN];Thymopentinum (Latin);Pentapeptide, Thymopoietin;O3Y80ZF13F;Thymopentin Acetate (TP-5);NSC645363;N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine;N-[N-[N-(N{2}-L-Arginyl-L-lysyl)-L-alpha-aspartyl]-L-valyl]-L-tyrosine;L-Tyrosine, N-(N-(N-(N2-L-arginyl-L-lysyl)-L-alpha-aspartyl)-L-valyl)-;NSC 760116;Thymopentin,(S);NCGC00166412-01;(3S)-3-(((2S)-6-amino-2-(((2S)-2-amino-5-(diaminomethylideneamino)pentanoyl)amino)hexanoyl)amino)-4-(((2S)-1-(((1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid;TP-5 Acetate;MFCD00214200;RKDVY;THYMOPENTIN [MI];THYMOPENTIN [INN];Thymopentin (USAN/INN);THYMOPENTIN [USAN];SCHEMBL44001;THYMOPENTIN [WHO-DD];MLS000069768;Arg-Lys-Asp-Val-Tyr; RKDVY;CHEMBL156025;Thymopentin, >=97% (HPLC);L03AX09;CHEBI:135870;PSWFFKRAVBDQEG-YGQNSOCVSA-N;SH-PENTAPEPTIDE-1 [INCI];HMS2231E14;HMS3264A15;Pharmakon1600-01506200;HY-N7122;Tox21_112420;NSC760116;AKOS015994638;CCG-270365;HS-2029;SMP1_000105;SMR000058921;CAS-69558-55-0;CS-0020412;S3668;imino-15-isopropyl-7,10,13,16-tetraoxo-;12-(carboxymethyl)-18-(4-hydroxybenzyl)-1-;D06117;2,8,11,14,17-pentaazanonadecan-19-oic acid;Q7799637;BRD-K52097716-001-01-1;L-Tyrosine, L-arginyl-L-lysyl-L-alpha-aspartyl-L-valyl-;(6S,9S,12S,15S,18S)-1,6-diamino-9-(4-aminobutyl)-;L-Tyrosine, L-arginyl-L-lysyl-L-.alpha.-aspartyl-L-valyl-;(3S)-3-[(2S)-6-AMINO-2-[(2S)-2-AMINO-5-CARBAMIMIDAMIDOPENTANAMIDO]HEXANAMIDO]-3-{[(1S)-1-{[(1S)-1-CARBOXY-2-(4-HYDROXYPHENYL)ETHYL]CARBAMOYL}-2-METHYLPROPYL]CARBAMOYL}PROPANOIC ACID;(6S,9S,12S,15S,18S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-18-(4-hydroxybenzyl)-1-imino-15-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecan-19-oicacid;
Chemical Name: (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C30H49N9O9 |
M.W/Mr. | 679.8 |
Sequence | One Letter Code:RKDVY Three Letter Code:H-Arg-Lys-Asp-Val-Tyr-OH |
Activity | Inhibitor |
Areas of Interest | AIDS |
Target | Mycobacteria phagocytosis |
Length | 3 |
Long-term Storage Conditions | DMF: 30 mg/ml DMSO: 25 mg/ml Ethanol: 1 mg/ml PBS (pH 7.2): 10 mg/ml |
Shipping Condition | Room Temperature in continental US; may vary elsewhere |
InChI | InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 |
InChI Key | PSWFFKRAVBDQEG-YGQNSOCVSA-N |
Canonical SMILES | CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CCCN=C(N)N)N |
Isomeric SMILES | CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.